DRW Securities LLC Buys Shares of 1,189 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

DRW Securities LLC acquired a new stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 1,189 shares of the pharmaceutical company's stock, valued at approximately $479,000.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 23,258,288 shares of the pharmaceutical company's stock valued at $9,366,113,000 after purchasing an additional 98,654 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Vertex Pharmaceuticals by 23.3% in the 4th quarter. Wellington Management Group LLP now owns 5,916,084 shares of the pharmaceutical company's stock worth $2,382,407,000 after buying an additional 1,117,214 shares during the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Vertex Pharmaceuticals by 23.0% during the fourth quarter. Loomis Sayles & Co. L P now owns 3,772,789 shares of the pharmaceutical company's stock worth $1,519,302,000 after buying an additional 704,575 shares in the last quarter. Norges Bank acquired a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth $1,374,948,000. Finally, Edgewood Management LLC raised its position in Vertex Pharmaceuticals by 91.2% in the fourth quarter. Edgewood Management LLC now owns 2,956,608 shares of the pharmaceutical company's stock valued at $1,190,626,000 after purchasing an additional 1,410,238 shares during the period. 90.96% of the stock is currently owned by institutional investors.

Remove Ads

Vertex Pharmaceuticals Stock Up 2.4 %

Vertex Pharmaceuticals stock traded up $11.61 during trading on Monday, reaching $495.83. 1,362,217 shares of the company's stock were exchanged, compared to its average volume of 1,326,199. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The firm has a market cap of $127.32 billion, a price-to-earnings ratio of -225.38, a PEG ratio of 2.11 and a beta of 0.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The company's 50-day moving average is $484.84 and its two-hundred day moving average is $464.28.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 530 shares of the business's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $475.34, for a total transaction of $251,930.20. Following the completion of the sale, the executive vice president now directly owns 58,539 shares of the company's stock, valued at approximately $27,825,928.26. The trade was a 0.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares of the company's stock, valued at $13,256,000. This trade represents a 10.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock worth $2,121,012 in the last ninety days. 0.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of analyst reports. Royal Bank of Canada increased their price target on Vertex Pharmaceuticals from $408.00 to $420.00 and gave the company a "sector perform" rating in a research report on Tuesday, April 1st. William Blair reissued an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Scotiabank raised their price target on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a report on Tuesday, February 11th. Wells Fargo & Company cut Vertex Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $460.00 price objective for the company. in a research report on Thursday, January 30th. Finally, Canaccord Genuity Group raised Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and boosted their target price for the company from $408.00 to $424.00 in a report on Tuesday, February 11th. Ten research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $512.41.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.